N. Kamar

N. Kamar is a nephrologist based in Toulouse whose presence in the volume links clinical investigation, evidence synthesis, and transplant medicine. His credited work treats hepatitis C not as an isolated liver disorder but as a systemic infection that can shape renal disease, dialysis outcomes, and the management of kidney transplant recipients. Across the book, his name marks a movement from identifying infection to deciding how its risks should be measured and treated.

Identity and Professional Setting

N. Kamar is listed among the contributors to the volume’s central chapter, “Hepatitis C and Renal Disease: Epidemiology, Diagnosis, Pathogenesis and Therapy,” alongside Jose M. Morales and Lionel Rostaing. The affiliation places him in the Department of Nephrology, Dialysis, and Organ Transplantation at CHU Rangueil in Toulouse, with a further connection to INSERM U563 and IFR-30. This institutional setting is significant: the chapter stands at the intersection of nephrology, dialysis, organ transplantation, virology, and clinical research rather than within a narrowly hepatic specialty.

His professional identity is also established through his contribution to “Treatment of Hepatitis C Virus Infection after Kidney Transplantation,” where he appears with Lionel Rostaing, Hugo Weclawiak, and Jacques Izopet. The pairing of these credited roles presents Kamar as a clinician working across the two decisive phases of care: recognizing the renal consequences of active infection before transplantation and determining how antiviral therapy can be used after a kidney has been implanted.

Hepatitis C as a Renal and Systemic Problem

The work associated with Kamar adopts the volume’s central premise that hepatitis C is a systemic disease. The infection can affect the liver while also producing autoimmune, dermatological, and renal disease, and it is described as both an important cause and a consequence of chronic kidney disease. This framework changes the clinical question. Hepatitis C is not merely a laboratory finding to be recorded before dialysis or transplantation; it becomes a condition that may influence renal pathology, survival, treatment eligibility, and the long-term behavior of an allograft.

The diagnostic structure is correspondingly precise. Chronic infection requires both anti-HCV antibodies and detectable HCV RNA in serum. Third-generation enzyme-linked immunosorbent assay identifies antibodies, but antibody positivity alone cannot distinguish resolved infection from active disease. Sensitive molecular assays, with a threshold of approximately 15 IU/ml, establish whether viral replication remains detectable. This distinction is especially important in nephrology and transplantation, where a patient’s status may determine the need for liver assessment, antiviral treatment, surveillance, or altered planning for kidney replacement therapy.

The chapter also places diagnosis within a broader evaluation of disease burden. With an estimated worldwide prevalence of about 3 percent, or roughly 170 million infected individuals, hepatitis C creates a public-health problem whose consequences extend beyond the initial infection. Screening is paired with assessment of extrahepatic effects such as cryoglobulinemia-associated vasculitis and evaluation of hepatic injury through liver biopsy or noninvasive markers of fibrosis. Kamar’s contribution therefore participates in a knowledge system that converts virologic status into a staged clinical profile: infection, organ involvement, fibrosis, treatment indication, and anticipated outcome.

Renal Manifestations and Treatment Logic

The renal disease discussed in Kamar’s coauthored chapter includes immune-mediated glomerular injury. Cryoglobulinemic membranoproliferative glomerulonephritis is identified as the most frequent HCV-related renal lesion, and renal disease is described as the principal cause of morbidity and mortality in patients with mixed cryoglobulinemia. The treatment consequence is direct: even when HCV-related liver injury by itself does not justify antiviral therapy, HCV-related renal disease requires specific treatment.

Treatment is organized according to severity. Moderate renal disease may be managed with anti-HCV therapy alone. Severe disease, defined by nephrotic syndrome, progressive renal failure, or failure to respond adequately to antiviral therapy, may require combined antiviral and immunosuppressive treatment. Supportive measures remain part of the clinical response, including blood-pressure control, diuretics, blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and treatment of hyperlipidemia. The resulting approach is neither purely antiviral nor purely nephrological: it combines suppression of the infection, control of immune injury, and protection of renal function.

Kamar’s broader therapeutic context is the transition from conventional therapy toward directly targeted drugs. Pegylated interferon and ribavirin produced sustained virologic response in more than half of patients with chronic infection, but more than half of genotype 1 patients failed to achieve that endpoint. The development of direct-acting antiviral drugs, including genotype 1-targeted protease and polymerase inhibitors and broader-spectrum agents, responded to that limitation. First-generation protease inhibitors increased sustained virologic response by approximately 20 to 30 percent in genotype 1 infection, while introducing new concerns about rash, anemia, cost, adherence, resistance, and drug interactions.

Dialysis, Transmission, and Institutional Responsibility

Kamar’s subject is also situated within the changing epidemiology of hepatitis C in hemodialysis. Once serological testing became available, dialysis patients were recognized as a high-risk population, partly because transfusions had been common and post-transfusion hepatitis had been frequent. Yet several observations supported continuing nosocomial transmission within dialysis units: prevalence correlated with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal or home dialysis, and remained substantial among some never-transfused patients.

The reduction in transfusion risk shifted attention toward infection-control practice. The risk of post-transfusion hepatitis C fell from approximately 0.5 percent per blood unit in the 1980s to about 0.0001 percent, or one case per million blood units, in the United States. Molecular investigations of newly diagnosed cases in dialysis units could not conclusively establish a specific transmission route, but all twenty reviewed studies suggested failures in infection-control procedures. In eighteen of the twenty studies, some or all newly infected patients had not shared a dialysis machine with the source patient, making the internal machine circuit, if involved at all, a comparatively minor route.

This evidence supports a policy distinction between equipment segregation and disciplined infection control. The KDIGO workgroup concluded that dedicated dialysis machines for HCV-infected patients were not recommended. It also found no randomized controlled trials proving that ward isolation was protective; two large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study, concluded that isolation did not prevent transmission after adjustment for relevant confounders. Isolation therefore was not recommended as a substitute for strict infection-control procedures. The institutional lesson attached to Kamar’s field is that risk is produced not only by the virus or the machine but by the organization of clinical work around blood, equipment, staff, and patients.

Survival and Kidney Transplantation

The evidence summarized in the volume shows that HCV infection carries an adverse survival association in both dialysis and transplant populations. A meta-analysis of seven observational studies involving 11,589 long-term dialysis patients found an independent relative risk of death of 1.34 for anti-HCV-positive patients. Liver-related mortality was especially elevated, with an unadjusted relative risk of 5.89 compared with anti-HCV-negative patients. A large Australia and New Zealand cohort of 23,046 patients similarly found an adjusted hazard ratio of 1.25 for all-cause mortality over ten years and an adjusted hazard ratio of 5.79 for hepatic failure, although hepatic failure remained an infrequent cause of death.

The transplant evidence is more nuanced than a simple comparison between infected and uninfected recipients. HCV-infected kidney transplant recipients generally have inferior long-term survival, and a meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79, partly explained by liver-related death. Yet transplantation still provides a survival advantage over remaining on dialysis or on the waiting list. In one comparison, HCV-positive patients receiving a kidney transplant had a relative risk of death of 0.31 during the 7-to-48-month post-transplant period compared with listed patients who remained without transplantation. In another analysis of 175 HCV-infected candidates, mortality risk was higher during the first six months after transplantation but fell to a hazard ratio of 0.32 during months 7 through 84.

This balance of risks makes pre-transplant evaluation essential. Studies found advanced liver injury, including stage 3 or 4 fibrosis and cirrhosis, in 10 to 25 percent of candidates who underwent biopsy. Candidates should be screened for anti-HCV antibodies and, where appropriate, active viremia by nucleic acid testing; patients with active infection require staging of liver disease, and liver biopsy remains the gold standard when advanced injury must be assessed. Established or decompensated cirrhosis should prompt referral to a liver transplant team for consideration of simultaneous liver-kidney transplantation. Patients remaining on the kidney transplant waiting list also require regular monitoring, particularly where waiting times may approach five to seven years.

The timing of antiviral treatment is therefore a central issue in Kamar’s transplant work. There is no universal consensus on treating active viremia before kidney transplantation, but achieving sustained virologic response before transplantation may reduce the risk of post-transplant diabetes and immune-complex glomerular disease in the allograft. Most patients who achieve sustained virologic response before transplantation do not relapse after immunosuppression is introduced. By contrast, interferon use after transplantation has been associated with an increased risk of allograft rejection, so efforts to eradicate HCV are directed preferentially to the pre-transplant period.

Narrative Role and Significance

N. Kamar’s role in the book is less that of a dramatized individual than of a specialist node in a larger medical knowledge network. His credited chapters bring together virologic classification, renal pathology, dialysis epidemiology, antiviral pharmacology, immune suppression, and transplant outcomes. The resulting portrait is one of medicine as coordinated decision-making: an antibody result must be separated from active RNA-positive infection; renal injury must be separated from liver injury; isolation must be separated from effective infection control; and transplantation must be weighed against, rather than abstractly opposed to, the dangers of continued dialysis.

His work also embodies the volume’s historical movement from the era of “non-A non-B hepatitis” toward molecular diagnosis, evidence-based guidelines, and direct-acting antiviral therapy. The disease becomes increasingly legible through antibodies, RNA assays, genotypes, fibrosis staging, registries, hazard ratios, and sustained virologic response. But the clinical problem does not disappear as it becomes more measurable. It persists in the consequences of infection for dialysis survival, the possibility of immune-complex renal disease, the vulnerability of a transplanted kidney, and the need to decide when treatment is safest. Kamar’s contribution is significant because it keeps those consequences within one continuous field of view, joining the laboratory definition of infection to the institutional and biological realities of renal care.